FDA records linked by MedtechLedger identify Medical AI Co., Ltd. as the applicant on a single 510(k) premarket notification in the retrieved collection, K254302, decided September 30, 2026. The filing covers ECG Analysis Software (AiTiALVSD) under product code QYE and regulation number 870.2380, Cardiovascular Machine Learning-Based Notification Software, in Class II. The company's own product pages describe a broader AiTiA Series and related ECG products, which are separate from the specific FDA clearance. [1][2][4]
The K254302 clearance and its scope
K254302 lists Medical AI Co., Ltd. as applicant, with a decision date of September 30, 2026 and decision code SESE, described as Substantially Equivalent. The device name in the record is ECG Analysis Software (AiTiALVSD); the openFDA device name field reads Reduced Ejection Fraction Machine Learning-Based Notification Software. The review advisory committee is Cardiovascular, the clearance type is Traditional, and the third-party flag is N. [1]
The FDA decision letter for K254302 names the trade device as AiTiALVSD, cites 21 CFR 870.2380 and regulatory Class II, and carries product code QYE. The letter is dated September 30, 2026 and addressed to a regulatory affairs contact at the Gangnam-Gu, Seoul address that also appears in the filing record. The letter's product description refers to the AiTiALVSD ECG-AI Low Ejection Fraction (LEF) 12-Lead Algorithm. [2]
The 510(k) database entry for K254302 links to the same decision letter PDF and to the product code QYE classification lookup. The page was last updated October 19, 2026. The retrieved collection contains one linked record, on the 510k pathway, with one SESE decision; the record sample likewise holds one entry, so the sample and collection counts coincide at this snapshot. [3]
Company-published product line
Medical AI's product page describes the AiTiA Series as a software diagnostic aid that analyzes ECGs and assesses AI disease risk scores, with ECG data passed through the AiTiA Series algorithm and results sent or shared. The same page lists a first series entry for Left Ventricular Systolic Dysfunction and references a Korean Ministry of Food and Drug Safety designation dated February 16, 2023, a Ministry of Health and Welfare announcement dated April 27, 2023, and the Public Procurement Service. [4]
The company's site describes its mission as connecting people with medical technology to address treatable and preventable diseases, and organizes its work around AiTiA ECG Center for hospitals, AiTiA Series for patients, and HeartSafe. A site notice dated September 15, 2026 concerns a record date for an extraordinary shareholders' meeting. These are company statements, not FDA findings. [5][6]
Published research involving the software
A prospective single-centre cohort study in European Heart Journal - Digital Health examined an AI-enhanced six-lead portable ECG device for detecting left ventricular systolic dysfunction. Its conflict-of-interest statement lists several authors as employees of Medical AI Co., Ltd. with equity or royalty relationships, and names one author as the company's founder. [7]
A Diagnostics paper published August 15, 2026 studied prediction of left ventricular systolic dysfunction with an AI-based ECG analysis model in emergency department patients. Its conflicts statement says Medical AI Co., Ltd. provided technical assistance with operation of the AiTiALVSD software but had no role in study design, data collection or interpretation, writing, or the decision to publish. [8]
A separate article addresses AI-driven ECG screening for asymptomatic left ventricular systolic dysfunction in the general population; the retrieved text identifies contributor contacts but does not state the company's role, which remains unknown from this source. [9]
Identity and record boundaries
The FDA applicant name is Medical AI Co., Ltd., matching the company name on its own website, which gives a Gangnam-gu, Seoul address and contact details. The FDA filing address is a regulatory correspondence address and does not by itself establish a headquarters. No parent, subsidiary or brand relationship is verified in these sources beyond the company's own naming of its AiTiA products. [1][2][4][5]
The retrieved collection covers one 510(k) record and no recall entries. That count describes the snapshot of linked filings, not total company sales, total portfolio or safety performance. Commercial availability, customers and clinical performance claims are not established by these documents. [1][3]
